Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832309 · ClinicalTrials.gov registry record · NA
Techniques to Reduce the Severity and Frequency of Emergent Reactions
A NA study, sponsored by CHRISTUS Health.
- Terminated
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT03832309: Clinical Trial NA study, sponsored by CHRISTUS Health.
NCT03832309 is a NA study that was terminated before completion, run by CHRISTUS Health. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03832309, a NA study, was terminated before completion, sponsored by CHRISTUS Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The objectives of this study are first to determine if the power of suggestion will decrease the frequency and severity of emergence reactions after procedural sedation and analgesia with ketamine in the setting of the emergency department. Second, to determine if people dream about what they were thinking about when they were induced with ketamine.
Primary Outcome
Data gathered from post sedation questionnaire, specifically question 5, will be analyzed by comparing the two means of group one and group two using a student's T test,
Interventions
- BEHAVIORAL Do we speak to them in a way that convinces them to have the dream
- BEHAVIORAL Speaking to them as a regualar person
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2021-06-21 |
| Phase | NA |
Why NCT03832309 stopped before completion
NCT03832309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Do we speak to them in a way that convinces them to have the dream is the first listed.
NCT03832309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03832309 about?
NCT03832309 is a clinical study titled "Techniques to Reduce the Severity and Frequency of Emergent Reactions". The objectives of this study are first to determine if the power of suggestion will decrease the frequency and severity of emergence reactions after procedural sedation and analgesia with ketamine in the setting of the emergency department. Second, to determine if people dream about what they were t...
What is the current status of trial NCT03832309?
This trial is currently terminated. It is a NA study. The enrollment target is 38 participants. The study started on 2017-11-21. Estimated completion is 2021-06-21.
What interventions are being tested in trial NCT03832309?
The interventions under investigation include: Do we speak to them in a way that convinces them to have the dream (BEHAVIORAL), Speaking to them as a regualar person (BEHAVIORAL).
Who is sponsoring clinical trial NCT03832309?
This trial is sponsored by CHRISTUS Health, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03832309's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI